Lilly launches once-weekly Victoza rival Trulicity; Actavis taps new CFO; Zealand recruits new chief;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. More | Follow @FiercePharma

@EricPFierce: Fresenius Russian partnership tanks even as Russian tanks spotted rolling into Ukraine. Story | Follow @EricPFierce

@CarlyHFierce: Dendreon bankruptcy weighs on cancer vaccine field. More | Follow @CarlyHFierce

> Eli Lilly ($LLY) said it rolled out its new diabetes drug Trulicity, which will compete with Novo Nordisk's blockbuster Victoza, in the U.S. Release

> Actavis ($ACT) brought in a new CFO, Maria Teresa Hilado, to replace the outgoing R. Todd Joyce; Hilado joins Actavis from PepsiCo, with a previous stint at Schering-Plough. Release

> Danish drugmaker Zealand Pharma has recruited Dako CEO Britt Meelby Jensen to take the reins, replacing current CEO David Solomon. Report

> Alexion Pharmaceuticals tapped SVP Julie O'Neill to replace its retiring co-founder Stephen Squinto as EVP and chief global operations officer. Report

> Portola Pharmacueticals, which is developing an antidote to newer blood-thinning medications, said it's on track with a pivotal study set for completion by the end of 2015. Release

Medical Device News

@FierceMedDev: China FDA's new medical device importation regulations shorten review period. More | Follow @FierceMedDev

@VarunSaxena2: Device that performs hundreds of tests with a single drop of blood wins Nokia Sensing Xchallenge. More | Follow @VarunSaxena2

> Thync rolling out wearable, noninvasive device to elevate mood with fresh infusion of cash in tow. More

> Medtronic makes concessions to European regulator in bid to close Covidien deal. News

> OrthAlign secures $15M to launch new navigation system for orthopedic surgery. Article

Biotech News

@FierceBiotech: Amgen takes another stride in frenzied race toward the PCSK9 finish line. More | Follow @FierceBiotech

@JohnCFierce: Triple shot IL-13/IL-4 -- Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII. More | Follow @JohnCFierce

@DamianFierce: I had missed this excellent tick-tock of the last days of one Christopher A. Viehbacher. More | Follow @DamianFierce

> Takeda recruits GE to help discover new liver treatments. Item

> Threshold shares surge as PhIII cancer program enters FDA's fast track. News

> AbbVie vies for the hep C spotlight on the eve of its Gilead battle. More

Biotech Research News

> Small human study will test a new approach to fighting diabetes. More

> Research team points to Sestrin 3 as a potential new target in diabetes. Article

> Harvard investigators prep an animal study of CRISPR Cas tech for HIV. Story

> Swiss team at ETH spotlights potential of a new antibiotic found in nature. More

> Genentech R&D team fixes a flawed approach to Alzheimer's. Report

Pharma Manufacturing News

> Cadila API plant slapped for faulty follow-up on stinking APIs. Article

> Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. Item

> Plant power outage zaps the juice from AMRI's earnings. More

> Dendreon, done in by expensive, complex manufacturing, files for bankruptcy. Story

> Fresenius expansion plans in Russia sidelined by political turmoil. Article

And Finally... The Obama administration expects 9.9 million people to sign up for health coverage under Obamacare this year, 3 million fewer than a previous estimate. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.